Wearable technology - IP opportunities and risks
16 August 2018 | 5:00 PM - 6:00 PM (BST)
Join us on 16 or 21 August for the fourth in our LimeGreen Live webinar series, in conjunction with the Hogan Lovells Consumer Industry Sector Group.
Representative experience
Advising large Japanese pharma company on its bid for a licence for a cancer drug from a UK biotechnology company involving a review of the patent situation in 19 jurisdictions.
Advising a public sector organization on the establishment of a US$800m SAP-based business transformation framework agreement.
Advising a manufacturer of construction equipment on IP licenses and technical services agreements in joint ventures with Chinese and Japanese entities.
Advising Genzyme on its strategic agreement with Bayer regarding Genzyme's hematologic oncology portfolio, including worldwide rights for Alemtuzumab (earn-out arrangement).
Hogan Lovells Publications
How to secure the right type of IP protection for wearable-technology products
23 April 2018
From wristbands that count your steps, to skin patches that measure your sun exposure, a wide range of products are entering the wearable-technology market and raising new questions about...
Blog Post
New Luxembourg IP Regime 2018
28 March 2018
Have you created, developed or improved inventions or copyrighted software since 31 December 2007 through research and development activities?
Hogan Lovells Publications
Brexit Effect Note: the legal Implications behind the headlines
14 April 2016
A comprehensive guide providing insight for businesses on the impact of a British exit from the EU. The impact for businesses will vary depending on the sector and markets businesses...
